Several MS drugs have been approved as disease-modifying therapies that include interferon beta (IFN-β), glatiramer acetate, natalizumab, fingolimod, alemtuzumab, teriflunomide, and dimethyl fumarate. The gene discussed is IFNB1; the disease is myeloid sarcoma.